Lonza announced the completion of the expansion of US$15 million multi-phase solid oral dose development and manufacturing capabilities at its Tampa, FL (USA) site.
The expansion included new product development suites for expanding powder-in-capsule / powder-in-bottle micro-dosing capacity for early-phase studies.
The expansion provides more integrated services for the customers across early-stage product development, clinical trial material manufacturing and commercialisation of innovative drug products.
The Lonza's Tampa site is one of the global networks for the design, development and manufacturing of drug materials and intermediates, particle engineering/bioavailability enhances drug products for oral and inhaled applications.
As part of the multi-year investment, the new site now boasts a fully equipped Product Development & QC Laboratory area with 13 processing suites and two new packaging suites for commercial packaging, including low-humidity environments and serialisation for complete tracking and tracing of products.
The expansion also included new manufacturing suites and progressive sampling and dispensing areas capable of handling highly potent compounds.
Also, expanded and renovated the cGMP manufacturing cleanroom facility, as well as completely renovating 25,000 sq ft of the existing cGMP OSD manufacturing cleanroom facility.
The expansion included encapsulation and micro-dosing capabilities for Xcelodose® Precision Powder Micro-Dosing Technology, Glatt GPCG-10 fluid bed processing and Harro Hoefliger Modu-C capsule filling.